Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
C 40.68 -0.12% -0.05
HALO closed down 0.12 percent on Thursday, March 28, 2024, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
20 DMA Resistance Bearish -0.12%
Stochastic Buy Signal Bullish -0.12%
Bollinger Band Squeeze Range Contraction -0.12%
NR7 Range Contraction -0.12%
Gapped Up Strength -0.12%
1,2,3 Pullback Bullish Bullish Swing Setup 1.50%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 16 hours ago
Rose Above Previous Day's High about 19 hours ago
20 DMA Resistance about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
10 DMA Support about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Halozyme Therapeutics, Inc. Description

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Solid Tumors Diabetes Antibodies Monoclonal Antibodies Enzymes Insulin Diabetes Mellitus Clinical Trial Product Halozyme Hoffmann La Roche Hyaluronidase Intrexon Nicu

Is HALO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.0
52 Week Low 29.85
Average Volume 1,168,843
200-Day Moving Average 38.45
50-Day Moving Average 37.92
20-Day Moving Average 40.93
10-Day Moving Average 40.46
Average True Range 1.08
RSI (14) 56.90
ADX 33.11
+DI 26.79
-DI 14.02
Chandelier Exit (Long, 3 ATRs) 39.41
Chandelier Exit (Short, 3 ATRs) 42.46
Upper Bollinger Bands 42.05
Lower Bollinger Band 39.80
Percent B (%b) 0.39
BandWidth 5.51
MACD Line 0.55
MACD Signal Line 0.79
MACD Histogram -0.2398
Fundamentals Value
Market Cap 5.37 Billion
Num Shares 132 Million
EPS 1.87
Price-to-Earnings (P/E) Ratio 21.75
Price-to-Sales 6.01
Price-to-Book 18.82
PEG Ratio -2.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.51
Resistance 3 (R3) 41.52 41.25 41.37
Resistance 2 (R2) 41.25 41.04 41.25 41.32
Resistance 1 (R1) 40.97 40.91 40.84 40.96 41.28
Pivot Point 40.70 40.70 40.64 40.70 40.70
Support 1 (S1) 40.42 40.49 40.29 40.41 40.08
Support 2 (S2) 40.15 40.36 40.15 40.04
Support 3 (S3) 39.87 40.15 39.99
Support 4 (S4) 39.86